The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Disease-Modifying Antirheumatic Drug Market Research Report 2025

Global Disease-Modifying Antirheumatic Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1545724

No of Pages : 92

Ask Your Query
Synopsis
It refers to drugs that can treat rheumatism, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, etc.
The global Disease-Modifying Antirheumatic Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Disease-Modifying Antirheumatic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Disease-Modifying Antirheumatic Drug.
Report Scope
The Disease-Modifying Antirheumatic Drug market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Disease-Modifying Antirheumatic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Disease-Modifying Antirheumatic Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Amgen
Pfizer
Roche Holding AG
Novartis International AG
Johnson & Johnson
Bristol-Myers Squibb
Merck
UCB S.A.
Eli Lilly and Company
Segment by Type
Non-Steroidal Anti-Inflammatory Drugs
Steroidal Anti-Inflammatory Drugs
Slow Acting Drug
Immunological Preparation
Segment by Application
Pharmaceutical Industry
Hospital and Clinic
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Disease-Modifying Antirheumatic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Disease-Modifying Antirheumatic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Disease-Modifying Antirheumatic Drug Market Overview
1.1 Product Overview and Scope of Disease-Modifying Antirheumatic Drug
1.2 Disease-Modifying Antirheumatic Drug Segment by Type
1.2.1 Global Disease-Modifying Antirheumatic Drug Market Value Comparison by Type (2024-2030)
1.2.2 Non-Steroidal Anti-Inflammatory Drugs
1.2.3 Steroidal Anti-Inflammatory Drugs
1.2.4 Slow Acting Drug
1.2.5 Immunological Preparation
1.3 Disease-Modifying Antirheumatic Drug Segment by Application
1.3.1 Global Disease-Modifying Antirheumatic Drug Market Value by Application: (2024-2030)
1.3.2 Pharmaceutical Industry
1.3.3 Hospital and Clinic
1.3.4 Other
1.4 Global Disease-Modifying Antirheumatic Drug Market Size Estimates and Forecasts
1.4.1 Global Disease-Modifying Antirheumatic Drug Revenue 2019-2030
1.4.2 Global Disease-Modifying Antirheumatic Drug Sales 2019-2030
1.4.3 Global Disease-Modifying Antirheumatic Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Disease-Modifying Antirheumatic Drug Market Competition by Manufacturers
2.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Disease-Modifying Antirheumatic Drug Average Price by Manufacturers (2019-2024)
2.4 Global Disease-Modifying Antirheumatic Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Disease-Modifying Antirheumatic Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Disease-Modifying Antirheumatic Drug, Product Type & Application
2.7 Disease-Modifying Antirheumatic Drug Market Competitive Situation and Trends
2.7.1 Disease-Modifying Antirheumatic Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Disease-Modifying Antirheumatic Drug Players Market Share by Revenue
2.7.3 Global Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Disease-Modifying Antirheumatic Drug Retrospective Market Scenario by Region
3.1 Global Disease-Modifying Antirheumatic Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Disease-Modifying Antirheumatic Drug Global Disease-Modifying Antirheumatic Drug Sales by Region: 2019-2030
3.2.1 Global Disease-Modifying Antirheumatic Drug Sales by Region: 2019-2024
3.2.2 Global Disease-Modifying Antirheumatic Drug Sales by Region: 2025-2030
3.3 Global Disease-Modifying Antirheumatic Drug Global Disease-Modifying Antirheumatic Drug Revenue by Region: 2019-2030
3.3.1 Global Disease-Modifying Antirheumatic Drug Revenue by Region: 2019-2024
3.3.2 Global Disease-Modifying Antirheumatic Drug Revenue by Region: 2025-2030
3.4 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.4.1 North America Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.4.3 North America Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.5.1 Europe Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.5.3 Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.7.1 Latin America Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.7.3 Latin America Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Disease-Modifying Antirheumatic Drug Sales by Type (2019-2030)
4.1.1 Global Disease-Modifying Antirheumatic Drug Sales by Type (2019-2024)
4.1.2 Global Disease-Modifying Antirheumatic Drug Sales by Type (2025-2030)
4.1.3 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2019-2030)
4.2 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2019-2030)
4.2.1 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2019-2024)
4.2.2 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2025-2030)
4.2.3 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2019-2030)
4.3 Global Disease-Modifying Antirheumatic Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Disease-Modifying Antirheumatic Drug Sales by Application (2019-2030)
5.1.1 Global Disease-Modifying Antirheumatic Drug Sales by Application (2019-2024)
5.1.2 Global Disease-Modifying Antirheumatic Drug Sales by Application (2025-2030)
5.1.3 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2019-2030)
5.2 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2019-2030)
5.2.1 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2019-2024)
5.2.2 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2025-2030)
5.2.3 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2019-2030)
5.3 Global Disease-Modifying Antirheumatic Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AbbVie Disease-Modifying Antirheumatic Drug Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Disease-Modifying Antirheumatic Drug Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Disease-Modifying Antirheumatic Drug Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Roche Holding AG
6.4.1 Roche Holding AG Corporation Information
6.4.2 Roche Holding AG Description and Business Overview
6.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Roche Holding AG Disease-Modifying Antirheumatic Drug Product Portfolio
6.4.5 Roche Holding AG Recent Developments/Updates
6.5 Novartis International AG
6.5.1 Novartis International AG Corporation Information
6.5.2 Novartis International AG Description and Business Overview
6.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis International AG Disease-Modifying Antirheumatic Drug Product Portfolio
6.5.5 Novartis International AG Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Johnson & Johnson Disease-Modifying Antirheumatic Drug Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Merck
6.8.1 Merck Corporation Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merck Disease-Modifying Antirheumatic Drug Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 UCB S.A.
6.9.1 UCB S.A. Corporation Information
6.9.2 UCB S.A. Description and Business Overview
6.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 UCB S.A. Disease-Modifying Antirheumatic Drug Product Portfolio
6.9.5 UCB S.A. Recent Developments/Updates
6.10 Eli Lilly and Company
6.10.1 Eli Lilly and Company Corporation Information
6.10.2 Eli Lilly and Company Description and Business Overview
6.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Product Portfolio
6.10.5 Eli Lilly and Company Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Disease-Modifying Antirheumatic Drug Industry Chain Analysis
7.2 Disease-Modifying Antirheumatic Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Disease-Modifying Antirheumatic Drug Production Mode & Process
7.4 Disease-Modifying Antirheumatic Drug Sales and Marketing
7.4.1 Disease-Modifying Antirheumatic Drug Sales Channels
7.4.2 Disease-Modifying Antirheumatic Drug Distributors
7.5 Disease-Modifying Antirheumatic Drug Customers
8 Disease-Modifying Antirheumatic Drug Market Dynamics
8.1 Disease-Modifying Antirheumatic Drug Industry Trends
8.2 Disease-Modifying Antirheumatic Drug Market Drivers
8.3 Disease-Modifying Antirheumatic Drug Market Challenges
8.4 Disease-Modifying Antirheumatic Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock